Immune response of AA broilers to IBV H120 vaccine and sodium new houttuyfonate

In this report, 120 healthy one-day-old AA broilers were divided into six groups. Groups 1–4 received 100, 200, 400 and 800 mg/L of sodium new houttuyfonate (SNH) with IB vaccine H120 respectively. Group 5 received PBS and H120 and group 6 IL-2 and H120. The chickens were inoculated at 7 and 14 days of age. On 0, 7, 14, 21, 28 and 35 post first vaccination, the dynamic changes of peripheral lymphocyte proliferation, cytokine assays and serum antibody titers were assayed respectively by MTT method, ELISA and hemagglutination inhibition assay (HI). The results showed that sodium new houttuyfonate significantly raised IB antibody titer in the chickens and also markedly promoted lymphocyte proliferation. The serum levels of IFN-γ and IL-4 in groups 1–4 were higher than those in groups 5 and 6. Hence, the immunologic enhancement of SNH was slightly superior to that of IL-2 adjuvant. Following challenge with IBV, chickens inoculated with SNH showed fewer and less severe clinical signs, lower death rate and less kidney pathology, as compared to those of the control groups. It indicated that SNH could enhance immune responses and increase protection against virulent IBV challenge in chickens.     

Evaluation of the antigen relatedness and efficacy of a single vaccination with different infectious bronchitis virus strains against a challenge with Malaysian variant and QX-like IBV strains

BackgroundThe predominant infectious bronchitis virus (IBV) strains detected in chickens in Malaysia are the Malaysian variant (MV) and QX-like, which are associated with respiratory distress, nephropathy, and high mortality. On the other hand, the antigenic relatedness and efficacy of IBV vaccines against these 2 field IBV strains are not well characterized.ObjectivesThis study aimed to determine the antigen relatedness and efficacy of different IB vaccine strains against a challenge with MV and QX-like strains.MethodsThe antigen relatedness and the ability of different IB vaccine strains in conferring protection against MV and QX-like were assessed based on the clinical signs, macroscopic lesions, and ciliary activity.ResultsThe MV strain IBS037A/2014 showed minor antigenic subtype differences with the vaccine virus Mass H120 and 4/91 strains but showed major antigenic subtype differences with the K2 strain. The Malaysian QX-like strain IBS130/2015 showed major antigenic subtype differences with the MV strain IBS037A/2014 and the vaccine strains except for K2. Chickens vaccinated once with Mass (H120) or with non-Mass (4/91 and K2) developed antibody responses with the highest antibody titer detected in the groups vaccinated with H120 and 4/91. The mean ciliary activities of the vaccinated chickens were between 56 to 59% and 48 to 52% in chickens challenged with IBS037A/2014 and IBS130/2015, respectively. The vaccinated and challenged birds showed mild to severe lesions in the lungs and kidneys.ConclusionsDespite the minor antigenic subtype differences, a single inoculation with Mass or non-Mass vaccines could not protect against the MV IBS037A/2014 and QX-like IBS130/2015.     

Protective immunity to infectious bronchitis in broilers vaccinated against Marek's disease either in ovo or at hatch and against infectious bronchitis at hatch

Two experiments were conducted using commercial broiler chickens to determine if Marek's disease (MD) vaccines HVT/SB-1 and HVT plus CVI-988 given either in ovo or at hatch adversely affected the efficacy of infectious bronchitis (IB) vaccines (Ark and Mass serotypes) given by eyedrop on the day of hatch. Nonvaccinated negative controls and controls that received only IB vaccines were included in each study. Birds were challenged with either infectious bronchitis virus (IBV) Mass-41 or IBV Ark-99 on either day 26 or 27 of age. Protection was assessed 5 days post-IBV challenged by virus isolation from the trachea. The day of hatch mean antibody titer to IBV was 12,668 +/- 4704 and 2503 +/- 3243 by enzyme-linked immunosorbent assay in experiments 1 and 2, respectively. In each study, nonvaccinated controls had a significantly higher (P < or = 0.05) incidence (88%-100%) of IBV challenge virus isolation than did controls vaccinated for IB but not for MD. Analysis of data from both studies showed that protection to IB in groups that received only IB vaccines at hatch ranged from 55.0% to 77.3%, whereas protection to IB in groups receiving both MD and IB vaccines ranged from 50.0% to 95.5%. In both experiments and within IBV challenge serotype, broilers given MD vaccines (in ovo or at hatch) and IB vaccines at hatch had protection rates to IBV challenges that were not significantly less (P < or = 0.05) than IB protection rates of groups that received only IB vaccines at hatch. Analysis of these data shows that administration of high-titered MD vaccines either in ovo or at hatch did not affect the efficacy of an IB vaccination (serotypes Ark and Mass) given by eyedrop at hatch.     

Serum antibody responses of chickens following sequential inoculations with different infectious bronchitis virus serotypes

Sequential inoculations of chickens with different live infectious bronchitis virus (IBV) antigenic types had major effects on virus-neutralization (VN) and hemagglutination-inhibition (HI) serum antibody responses. Antibody production in IBV-inoculated chickens that were reinoculated 8 weeks later with heterologous virus was largely directed against the virus used for initial inoculation rather than the virus used for reinoculation. In addition, chickens inoculated sequentially with IBV produced a broadened spectrum of serum antibodies that reacted with IBV types to which the birds had never been exposed (JMK and Florida). Chickens inoculated sequentially with heterologous IBV tended to produce higher levels of cross-reacting antibody than birds given homologous virus inoculations. Levels of cross-reacting antibodies were lower than levels of specific antibodies directed against viruses that the birds had received. Limited studies indicated that birds with cross-reacting antibodies were not protected against challenge with the virus that the cross-reacting antibody was directed against. Implications of the research for interpreting serological data from commercial chicken flocks are discussed.     

Production and immunogenicity of chimeric virus-like particles containing the spike glycoprotein of infectious bronchitis virus

Infectious bronchitis virus (IBV) poses a severe threat to the poultry industry and causes heavy economic losses worldwide. Vaccination is the most effective method of preventing infection and controlling the spread of IBV, but currently available inactivated and attenuated virus vaccines have some disadvantages. We developed a chimeric virus-like particle (VLP)-based candidate vaccine for IBV protection. The chimeric VLP was composed of matrix 1 protein from avian influenza H5N1 virus and a fusion protein neuraminidase (NA)/spike 1 (S1) that was generated by fusing IBV S1 protein to the cytoplasmic and transmembrane domains of NA protein of avian influenza H5N1 virus. The chimeric VLPs elicited significantly higher S1-specific antibody responses in intramuscularly immunized mice and chickens than inactivated IBV viruses. Furthermore, the chimeric VLPs induced significantly higher neutralization antibody levels than inactivated H120 virus in SPF chickens. Finally, the chimeric VLPs induced significantly higher IL-4 production in mice. These results demonstrate that chimeric VLPs have the potential for use in vaccines against IBV infection.     

Transmissibility of infectious bronchitis virus H120 vaccine strain among broilers under experimental conditions

The aim of this study was to quantify transmission of infectious bronchitis virus (IBV) H120 vaccine strain among broilers, and to assess whether birds that have been exposed to vaccine strain-shedding birds were protected against clinical signs after infection with a virulent strain of the same serotype. A transmission experiment and a replicate were carried out, each with six groups of commercial broilers. At day of hatch (n = 30) or at 15 days of age (n = 20), half of each group was inoculated with either IBV H120 vaccine (H120 group), virulent IBV M41 (M41 group), or were mock-infected, thereby contact-exposing the other half of each group. Nasal discharge was recorded, and antibody response and virus shedding were measured. To measure clinical protection, four weeks after inoculation all birds, in all groups, were challenged with IBV M41. The reproduction ratio (R; the average number of contact infections caused by one infectious bird) was determined to quantify virus transmission. All contact-exposed birds, except for one in an H120 group, became infected with either IBV H120 or IBV M41. Almost all birds contact-infected with IBV H120 or IBV M41 were subsequently protected against clinical signs after challenge with IBV M41. The lower limits of the 95% confidence interval (CI) of the R of IBV H120 vaccine, and of IBV M41, were significantly <1. For both IBV H120 and IBV M41, the 95% CI was [2.1-infinity] following inoculation at day of hatch and [1.8-infinity] after inoculation at 15 days of age. This finding demonstrates that IBV H120 vaccine is able to spread extensively among broilers. This implies that this vaccine strain might be able to become endemically present in the poultry population. It also implies that, even if not all birds received vaccine during spray application, due to the ability of the vaccine to spread in the flock, they will most likely be protected against clinical signs after a subsequent field virus infection.     

Infectious bronchitis virus nucleoprotein specific CTL response is generated prior to serum IgG

Infectious bronchitis (IB) is an acute and highly contagious viral respiratory disease of chickens. To understand the kinetics and relationships between the humoral (Ab) and antigen specific T cell immunity as well as pathological changes during infectious bronchitis virus (IBV) infection and immunization, one-week-old SPF chickens were vaccinated with live IBV H52 strain and challenged with IBV M41 15 days post primary infection. Chickens were sacrificed every 3 days to monitor antigen specific serum IgG and IBV nucleoprotein-specific immune responses using a chicken MHC I tetramer developed in our laboratory. The results demonstrated that T cell responses developed more rapidly than the humoral (Ab) immune response after vaccination with H52. However, serum IgG dramatically increased after M41 challenge. Chickens from the control, non-vaccinated group developed severe respiratory symptoms and demonstrated significant pathological changes in lung, kidney and bursa of Fabricius post challenge with M41. However, chickens vaccinated with H52 did not demonstrate clinical signs or histological changes post challenge with M41. These results indicated that the live IBV H52 inoculation effectively protected chickens from morbidity and pathological changes associated with IBV infection. These data facilitates the design of a new generation of IBV vaccine.     

鸡滑液囊支原体活疫苗(MS-H株)同时免疫对新支二联活疫苗免疫效力影响的调查

为了解新支二联活疫苗和鸡滑液囊支原体活疫苗之间有无相互影响,选用70只1日龄SPF鸡随机分为4组进行比对试验,其中:G1组20只,联合免疫新支二联苗活疫苗和鸡滑液囊支原体活疫苗(MS-H株);G2组20只,为新支二联活疫苗单独免疫组;G3组20只,为传染性支气管炎病毒(IBV)攻毒组;G4组10只,为空白对照组。免疫后21 d时采血,血凝抑制(HI)试验进行新城疫(ND)血清抗体检测,同时G1、G2和G3组IBV强毒点眼攻毒,并于攻毒后第5天剖检,进行气囊评分。所有试验鸡剖检时,采集气管进行IBV再分离及病理观察。结果:G1和G2组的NDV抗体阳性率分别为94.74%和100%,其平均效价分别为4.26和4.35,剩余2组阳性率均为0;气管IBV再分离结果显示G1和G2组新支二联苗的保护率分别为88.24%和89.47%;气管病理学观察显示G3组出现了典型的传染性支气管炎(IB)病理变化,而G1组和G2组未出现明显IB病理变化。研究表明,同时免疫MS-H活疫苗并未对新支二联活疫苗的免疫效力产生影响。     

Ciliary activity: a criterion for associating resistance to infectious bronchitis virus infection with ELISA antibody titer

Vaccination and challenge experiments using infectious bronchitis virus (IBV) were conducted on groups of specific-pathogen-free chickens. Three weeks post-vaccination with one of the four IBV strains used, chickens were challenged with the homologous immunizing strain of IBV. Subsequently, the chickens were sacrificed, their tracheas were examined for ciliostasis, and the specific IBV antibody content of their sera was measured by enzyme-linked immunosorbent assay (ELISA). Results showed that protection was conferred by primary vaccination, as ciliostasis was not observed in tracheas from groups vaccinated and then challenged. No protection was observed in control groups that received only a challenge exposure, and the virus was readily recovered from their tracheas. Homologous protection was present in chickens that had ELISA titers as low as 624 and neutralization indices as low as 2.9, whereas susceptible controls had titers of less than 100 and less than 1.0, respectively.     

几种病毒与禽病原性大肠杆菌的人工联合感染

以2种剂量的低致病性禽流感病毒(lowly pathogenic avian influenza virus,LPAIV)，传染性支气管炎病毒（infectious bronchitis virus,IBV)疫苗株H120和H52，新城疫病毒（Newcastle disese viurs,NDV)Lasota株分别于气管内注射10日龄易感鸡，2d后，气管注射禽病原性大肠杆菌O37株（O78），连续观察5d，结果，除LPAIV单独感染组有6．25％的死亡率外，其余各病毒单独接种组均健活；大肠杆菌O37株单独接种组的死亡率为62．50％，较高剂量的LPAIV，IBV H120和H52，NDV Lasota株与大肠杆菌O37株有效强的协同致病作用，死亡率分别达到81.25%,100.00%,93.75%和87.50%，而较低剂量的上述病毒则无明显的协同作用，IBV，NDV疫苗株与大肠杆菌联合接种组的多数死亡鸡病程推迟。     

Effect of IBV-H120 vaccination in broilers on colibacillosis susceptibility after infection with a virulent Massachusetts-type IBV strain

Vaccination against infectious bronchitis (IB) is aimed to protect against clinical IB. The question is, however, whether vaccinated birds are also protected against predisposure for colibacillosis after a subsequent IBV infection. We examined this research question in four experiments. One-day-old commercial broilers, housed in isolators, were vaccinated with IB vaccine strain H120 by coarse spray or ocularly. Twenty-eight days after vaccination, broilers were challenged with the virulent IBV strain M41. Five days later, broilers were inoculated with Escherichia coli strain 506. Body weight uniformity, severity of E. coli airsacculitis, and systemic E. coli infection at 7 days following E. coli inoculation were used as parameters for colibacillosis. IBV vaccination reduced both the number of broilers with E. coli airsacculitis as well as the severity of airsacculitis significantly after challenge with IBV-M41 and E. coli 506. However, in spray-vaccinated groups, no significant reduction of the number of birds with systemic colibacillosis or the severity of this infection was obtained, and body weight uniformity was not significantly improved compared with nonvaccinated, IBV-M41, and E. coli 506-challenged groups. Eye-drop vaccination resulted in conflicting results.     

合成鱼腥草素对鸡新城疫疫苗免疫增强效果的研究

为探讨合成鱼腥草素对鸡新城疫疫苗免疫增强效果的影响,本试验将160只7日龄非免疫健康雏鸡随机分为空白对照组和低、中、高3个剂量组,各组用NDV La Sota株弱毒活疫苗进行初免,2周后加强免疫1次,并在第2次免疫的当天灌胃给药,3个剂量组分别以50、100和150 mg/kg的剂量灌服合成鱼腥草素,连续给药7 d,空白对照组灌服等量的生理盐水.各组分别于初免后的14、21、28和35 d随机抽取8只鸡,测定其免疫器官指数,血清中IFN-γ、IL-2和IL-4的含量及新城疫抗体的效价.结果表明,不同剂量的合成鱼腥草素均能不同程度地提高肉鸡免疫器官指数、细胞因子和抗体滴度的水平,其中以中剂量(100 mg/kg)效果最明显.     

Protective immune responses induced by in ovo immunization with recombinant adenoviruses expressing spike (S1) glycoprotein of infectious bronchitis virus fused/co-administered with granulocyte-macrophage colony stimulating factor

Infectious bronchitis virus (IBV) causes tremendous economic losses associated with production inefficiencies and mortality in poultry industry worldwide. In the present report, the recombinant adenoviruses expressing chicken granulocyte-macrophage colony stimulating factor (GM-CSF) and S1 gene of nephropathogenic IBV were constructed and characterized. Then, the immunological efficacy and protection against homologous IBV challenge were assessed in specific pathogen free (SPF) chickens. The results showed that the chickens vaccinated in ovo with rAd-S1, rAd-GM-S1 (GM-CSF fused with S1 using glycine linkers) and rAd-GM-CSF plus rAd-S1 (co-administered) developed specific anti-IBV HI antibodies. Moreover, the fusion of the GM-CSF markedly increased spleen cell proliferation and IFN-γ production while mild increased in IL-4 production, which demonstrated the enhancement of cell-mediated immune responses. Following challenge with IBV, the chickens in the group vaccinated with rAd-S1 fused or co-administered with GM-CSF had fewer nephropathic lesions and showed 100% protection as compared to that of rAd-S1 alone which showed 70% protection. It indicated that the single dose in ovo vaccination of the GM-CSF fused or co-administered with S1 of IBV could enhance significantly the humoral, cellular immune responses and provide complete protection against nephropathogenic IBV challenge. This finding may provide basic information for effective in ovo vaccines design against IBV.     

Occurrence and significance of infectious bronchitis virus variant strains in egg and broiler production in the Netherlands

Despite vaccination against Infectious bronchitis virus (IBV) with the Massachusetts type vaccine viruses H120 and H52 in the Netherlands, an increasing number of properly vaccinated flocks have suffered from the disease since 1978. In the years 1978-1982, the virus was isolated from 162 IBV suspected flocks. Cross-virus-neutralization tests showed that the majority (67 per cent) of these isolates belonged to serotypes other than the Massachusetts type, the Connecticut-, Florida-, Iowa 97-, Iowa 609- and JMK serotype. The majority of these Dutch isolates could be divided into 4 serogroups, called D207, D212, D3128 and D3896. Only a few isolates were not related to these serotypes. A survey of 328 flocks for antibody against these serotypes demonstrated that antibody against one or more of these novel serotypes were present in most of the flocks. Experiments demonstrated that vaccination with the H120 vaccine virus was not able to protect chickens against the adverse effects of a challenge with the novel serotypes.     

不同来源传染性支气管炎病毒诱导SPF鸡发病的免疫机制研究

试验旨在探讨不同来源的传染性支气管炎病毒(Infectious bronchitis virus,IBV)诱导SPF鸡发病的免疫机制。选用140只1日龄SPF白来航鸡,随机分为4组,3组攻毒组通过滴鼻点眼途径分别接种鸡源IBV强毒株、鸡源IBV弱毒株和野鸡源IBV毒株3个毒株,对照组以同种方式接种等量灭菌的磷酸盐缓冲液。在感染后12 h、36 h、72 h、7 d和14 d,每组随机选取5只进行剖检,并分别采集法氏囊、肾脏和气管组织,剩余鸡用于观察临床症状、发病及死亡情况。应用实时荧光定量PCR检测攻毒后不同时间点采集的各组织中IBV的病毒载量、Toll样受体(Toll-like receptors,TLRs)及部分细胞因子(白细胞介素(interleukin,IL)和干扰素(interferon,IFN))表达量的变化。结果显示,感染不同来源IBV毒株之后仅鸡源IBV强毒株感染组SPF鸡出现抑郁、翅膀下垂、甩头等典型的临床症状,且在感染后5~10 d共有7只死亡,死亡率为20%。病理剖检发现,感染鸡源IBV强毒株的鸡肾脏肿大、尿酸盐沉积和有花斑样病变,而感染野鸡源IBV毒株、鸡源IBV弱毒株和对照组的鸡无明显的眼观病变。实时荧光定量PCR结果显示,在鸡源IBV强毒株组的法氏囊、肾脏和气管3个组织中均检测到病毒。对照组和野鸡源IBV毒株组中均未检测到病毒,鸡源IBV弱毒株组只在部分组织中检测到病毒。在感染后72 h,鸡源IBV强毒株组与其他各组相比,TLR1、TLR2、TLR3、TLR5、TLR7和TLR15基因在法氏囊中的表达量均显著升高(P<0.05),IL-6和IFN-β参与更强烈的抗病毒免疫反应;在感染后7 d,鸡源IBV弱毒株组与其他各组相比,肾脏中TLR2、TLR3、TLR15、TLR21、IL-6和IL-18基因表达量均显著升高(P<0.05)。野鸡源IBV感染后36 h法氏囊组织中IFN-γ基因表达量显著上调(P<0.05)。综上所述,3个IBV毒株中仅鸡源IBV强毒感染引起SPF鸡典型临床发病症状与可视组织病变,且可提高SPF鸡组织中免疫相关因子的基因表达量。本研究结果揭示,不同来源的IBV对SPF鸡的不同致病性与其感染诱导的免疫反应不同有关。     

Immunosuppressive effect of a highly virulent infectious bursal disease virus isolated in Japan.

The immunosuppressive effect of infectious bursal disease virus (IBDV) on vaccination against Newcastle disease (ND) was compared among 2-, 3-, and 4-week-old chickens inoculated with the highly virulent IBDV field isolate 90-11 and the reference serotype 1 strain GBF-1. In all age groups, isolate 90-11 severely suppressed antibody response to ND vaccination and protective vaccinal immunity against ND. In contrast, chickens inoculated with strain GBF-1 and vaccinated with ND vaccine were well protected from the ND virus challenge. The mitogenic response to phytohemagglutinin of splenic lymphocytes from chickens inoculated with isolate 90-11 or strain GBF-1 was significantly lower than that of uninoculated controls. There was no difference between the two inoculated groups in responsiveness, although lymphocyte depletion in the thymus was more severe in chickens inoculated with isolate 90-11 than in chickens inoculated with strain GBF-1.     

鸡传染性支气管炎强毒分离株遗传进化分析和免疫保护试验

从山东省发病鸡群中分离鉴定了一株鸡传染性支气管炎病毒（Infectious bronchitis virus,IBV）强毒株SDIB821/2012,对其进行S1基因序列测定分析和免疫保护试验。S1基因遗传进化分析结果显示,SDIB821/2012属于以QXIBV为代表的基因型,与同属一个基因型的IBV参考株氨基酸同源性为91.6%～98.5%,与疫苗株491同源性为77.6%,与H120和MA5同源性均为74.8%。免疫保护试验结果显示,根据试验鸡临床症状和发病死亡情况,弱毒活疫苗491对SDIB821/2012的保护率为90%,而H120和MA5对SDIB821/2012的保护率分别仅为40%和33%。攻毒后各免疫组喉头、泄殖腔棉拭样品以及气管、肺脏和肾脏组织均可检测到病毒,表明3种IB疫苗均不能对SDIB821/2012提供完全的免疫保护。     

黄芪灵芝口服液对免疫新城疫疫苗雏鸡免疫功能的影响

为研究黄芪灵芝口服液对雏鸡免疫功能的影响,本试验将180只14日龄雏鸡随机分成9组并通过点眼滴鼻免疫新城疫(ND)疫苗。1~3组分别是黄芪灵芝口服液高、中和低剂量组;4~6组分别是环磷酰胺+黄芪灵芝口服液高、中和低剂量组;7~9组分别为环磷酰胺组、阳性对照组及生理盐水对照组。分别于免疫后的第7、14、21、28天测定脾脏淋巴细胞增殖和抗体滴度的动态变化。结果表明,黄芪灵芝口服液能提高雏鸡脾脏淋巴细胞的增殖能力和促进新城疫病毒(NDV)抗体的产生,能一定程度上缓解环磷酰胺的免疫抑制,其中黄芪灵芝口服液低剂量组对脾脏淋巴细胞增殖效果最好,黄芪灵芝口服液可作为一种新型的免疫增强剂。     

Effects of the Oral Liquid of Astragalus and Lucidum Polysaccharides on Immunological Function in Chickens Immuned with ND Vaccine

In order to study the effects of the oral liquid of Astragalus and Lucidum polysaccharides on immunological function in chickens,one hundred and eighty 14-day-old chickens were randomly divided into 9 groups and inoculated with the Newcastle disease vaccine.1 to 3 experimental groups were respectively the oral liquid of Astragalus and Lucidum polysaccharides high,middle and low dose groups;4 to 6 experimental groups were respectively the oral liquid of Astragalus and Lucidum polysaccharides with cyclophosphamide high,middle and low dose groups;7 to 9 experimental groups were respectively cyclophosphamide group,positive control group and saline control group.The proliferation index of spleen lymphocyte and Newcastle disease virus antibody level by HI method were determined on days 7,14,21 and 28 after vaccination.The results showed that the oral liquid of Astragalus and Lucidum polysaccharides could apparently promote lymphocyte proliferation and enhance antibody titer,and alleviate the immunosupperession of the chickens in some degree,the low dose of the oral liquid of Astragalus and Lucidum polysaccharides promoted lymphocyte proliferation best,implying that the oral liquid of Astragalus and Lucidum polysaccharides would be expected as a candidate of new-type immunopotentiator.